fbpx
QQQ
+ 0.00
324.13
+ 0%
DIA
+ 0.00
319.49
+ 0%
SPY
+ 0.00
391.84
+ 0%
TLT
+ 0.00
140.84
+ 0%
GLD
+ 0.00
168.98
+ 0%

Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest EPS Growth Forecast For Next 5 Years

by
June 19, 2015 4:43 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest EPS Growth Forecast For Next 5 Years

Below are the top drugs-generic stocks on the NASDAQ in terms of EPS growth forecast for the next five years.

Evoke Pharma Inc (NASDAQ: EVOK) earnings per share growth forecast for the next five years is 40.00 percent. Evoke Pharma has a market capitalization of $33.54 million.

Steadymed Ltd (NASDAQ: STDY) EPS growth forecast for the next five years is 37.50 percent. Steadymed’s trailing-twelve-month EPS is -$1.78.

Sagent Pharmaceuticals Inc (NASDAQ: SGNT) EPS growth forecast for the next five years is 26.68 percent. Sagent Pharmaceuticals’ PEG ratio is 0.91.

Akorn, Inc. (NASDAQ: AKRX) earnings per share growth forecast for the next five years is 23.72 percent. Akorn’s trailing-twelve-month ROE is 11.10 percent.

Posted-In:

Trading Ideas

Related Articles

33 Stocks Moving in Wednesday's Pre-Market Session

Gainers Greenpro Capital Corp. (NASDAQ: GRNQ) shares rose 47.8% to $1.22 in pre-market trading after jumping over 33% on Tuesday. read more

96 Biggest Movers From Yesterday

Gainers Mmtec, Inc. (NASDAQ: MTC) shares climbed 86.4% to close at $2.05 on Tuesday after reporting its financial results for the year ended December 31, 2019. Revenues jumped 647% to $200,797, in 2019. read more

61 Stocks Moving In Tuesday's Mid-Day Session

Gainers Mmtec, Inc. (NASDAQ: MTC) shares jumped 98.2% to $2.18 in pre-market trading after reporting its financial results for the year ended December 31, 2019. Revenues jumped 647% to $200,797, in 2019. read more

28 Stocks Moving in Tuesday's Pre-Market Session

Gainers Mmtec, Inc. (NASDAQ: MTC) shares rose 77.2% to $1.95 in pre-market trading after reporting its financial results for the year ended December 31, 2019. Revenues jumped 647% to $200,797,in 2019. read more